Histology
Transitional Cell Carcinoma
CI-CAN-00001613Explore in graph →
253 active trials5 approved drugs22 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001613Explore in graph →
Clinical trials
734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (119)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 579 | National Cancer Institute (NCI)NIH | 4 | Sep 29, 2026 | clinicaltrials |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | active not recruiting | Phase 2 / Phase 3 | 582 | National Cancer Institute (NCI) |
| 5 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT06331299 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer(UTOPIA) | active not recruiting | Phase 3 | 99 | UroGen Pharma Ltd.INDUSTRY | 7 | Sep 28, 2026 | clinicaltrials |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | active not recruiting | Phase 3 | 184 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03244384 | Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer(AMBASSADOR) | active not recruiting | Phase 3 | 739 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03775265 | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | active not recruiting | Phase 3 | 475 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05911295 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | active not recruiting | Phase 3 | 412 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 24 | Jul 22, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | active not recruiting | Phase 3 | 367 | CG Oncology, Inc.INDUSTRY | 2 | Jul 1, 2026 | clinicaltrials |
| NCT03967977 | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma | active not recruiting | Phase 3 | 420 | BeiGeneINDUSTRY | 2 | Jun 22, 2026 | clinicaltrials |
| NCT05092958 | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | active not recruiting | Phase 3 | 654 | National Cancer Institute (NCI)NIH | 2 | Jun 12, 2026 | clinicaltrials |
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 692 | National Cancer Institute (NCI)NIH | 3 | May 29, 2026 | clinicaltrials |
| NCT05243550 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ENVISION) | active not recruiting | Phase 3 | 240 | UroGen Pharma Ltd.INDUSTRY | 10 | May 11, 2026 | clinicaltrials |
| NCT03091660 | S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer | active not recruiting | Phase 3 | 1,000 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04637594 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy(IMAGINE) | active not recruiting | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT06462001 | BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer | active not recruiting | Phase 3 | 500 | Nottingham University Hospitals NHS TrustOTHER | 1 | Jun 17, 2024 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials